TriangleDISEASE & TREATMENT SETTING
refractory Mantle Cell Lymphoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Broader topic: Mantle Cell Lymphoma
- Source population
- Not part of this definition
- Disease extent
- refractory
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- prior therapy
- status
- stated
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Study evidence for this setting
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolim
Indication-specific source history
2020-07-24 · Tecartus (brexucabtagene autoleucel) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma-refractory-4c55fb44
- event id
- fda-04e2e60bc99c19d3
- event date
- 2020-07-24
- event kind
- accelerated-approval
- drug or regimen
- Tecartus (brexucabtagene autoleucel)
- source indication text
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
- match phrase
- refractory mantle cell lymphoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b5d3c853ddc4e9301e35
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-13 · Beqalzi (sonrotoclax) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma-refractory-4c55fb44
- event id
- fda-17e67f73de17f8ad
- event date
- 2026-05-13
- event kind
- accelerated-approval
- drug or regimen
- Beqalzi (sonrotoclax)
- source indication text
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
- match phrase
- refractory mantle cell lymphoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b902c006dd7cbee0434b
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-13 · sonrotoclax · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma-refractory-4c55fb44
- event id
- notice-3c8c617ecb9d3d1c
- event date
- 2026-05-13
- event kind
- approval-notification
- drug or regimen
- sonrotoclax
- source indication text
- FDA approved sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.
- match phrase
- refractory mantle cell lymphoma
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-e3ca63e98a156ea8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice